PE20031052A1 - Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 - Google Patents

Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Info

Publication number
PE20031052A1
PE20031052A1 PE2003000166A PE2003000166A PE20031052A1 PE 20031052 A1 PE20031052 A1 PE 20031052A1 PE 2003000166 A PE2003000166 A PE 2003000166A PE 2003000166 A PE2003000166 A PE 2003000166A PE 20031052 A1 PE20031052 A1 PE 20031052A1
Authority
PE
Peru
Prior art keywords
alpha
cycloxygenase
combinations
selective inhibitor
delta ligand
Prior art date
Application number
PE2003000166A
Other languages
English (en)
Spanish (es)
Inventor
Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20031052A1 publication Critical patent/PE20031052A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PE2003000166A 2002-02-22 2003-02-17 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 PE20031052A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
PE20031052A1 true PE20031052A1 (es) 2003-12-24

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000166A PE20031052A1 (es) 2002-02-22 2003-02-17 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (enExample)
EP (1) EP1480639A1 (enExample)
JP (1) JP2005523281A (enExample)
KR (1) KR20040085216A (enExample)
CN (1) CN1635887A (enExample)
AR (1) AR038531A1 (enExample)
AU (1) AU2003246864A1 (enExample)
BR (1) BR0307906A (enExample)
CA (1) CA2476438A1 (enExample)
CO (1) CO5611109A2 (enExample)
HN (1) HN2003000071A (enExample)
IL (1) IL162932A0 (enExample)
MX (1) MXPA04008175A (enExample)
NO (1) NO20043947L (enExample)
PA (1) PA8567201A1 (enExample)
PE (1) PE20031052A1 (enExample)
PL (1) PL372210A1 (enExample)
RU (1) RU2286151C2 (enExample)
TW (1) TW200303214A (enExample)
UY (1) UY27675A1 (enExample)
WO (1) WO2003070237A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
BRPI0709961A2 (pt) * 2006-04-11 2011-08-02 Novartis Ag compostos orgánicos
EA200900821A1 (ru) * 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CA3200132A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
CA2193384C (en) * 1994-07-27 2002-03-19 Geoffrey Neil Woodruff Use of gabapentin in the treatment of anxiety and panic
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
CN1279667A (zh) * 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代-4(3)-氨基甲基-(硫代)吡喃(噻喃)或-哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions

Also Published As

Publication number Publication date
US20030199567A1 (en) 2003-10-23
RU2004125609A (ru) 2006-01-27
CA2476438A1 (en) 2003-08-28
CN1635887A (zh) 2005-07-06
UY27675A1 (es) 2003-09-30
AR038531A1 (es) 2005-01-19
RU2286151C2 (ru) 2006-10-27
NO20043947L (no) 2004-09-21
HN2003000071A (es) 2003-11-24
JP2005523281A (ja) 2005-08-04
PA8567201A1 (es) 2003-11-12
TW200303214A (en) 2003-09-01
MXPA04008175A (es) 2004-11-26
KR20040085216A (ko) 2004-10-07
IL162932A0 (en) 2005-11-20
AU2003246864A1 (en) 2003-09-09
CO5611109A2 (es) 2006-02-28
PL372210A1 (en) 2005-07-11
EP1480639A1 (en) 2004-12-01
BR0307906A (pt) 2004-12-21
WO2003070237A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
PE20040760A1 (es) C-aril-glucosidos como inhibidores de sglt2
HN2001000010A (es) Sintesis asimetrica de pregabalin
BR9812133A (pt) Análogos de gaba para prevenir e tratar danos gastrintestinais
CR6883A (es) Composiciones farmaceuticas de inhibidores de la potencia de colesteril ester
NO20044034L (no) ACC inhibitorer
BR0314196A (pt) Inibidores de tgf-beta
ATE374917T1 (de) Zerlegbares gewehr
DE50104973D1 (de) Präpolymere (meth)acrylate mit polycyclischen oder aromatischen segmenten
ATE283051T1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
ES2571730T3 (es) Composiciones farmacéuticas que comprenden droxidopa
AR038531A1 (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
EA200600465A1 (ru) Ингибиторы каспазы, содержащие изоксазолиновый цикл
CY1112318T1 (el) Εξωτερικο παρασκευασμα για διαδερμικη χορηγηση που περιεχει μη στεροειδες αντι-φλεγμονωδες αναλγητικο
SE0001162D0 (sv) Projektil
BR0318170A (pt) unidade divisora de uma tubuladura de válvula de estrangulamento
WO2004065844A3 (en) Method and apparatus for charging efflorescent material utilizing ultra violet light
FR2848116B1 (fr) Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide.
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
DK1100793T3 (da) Krystalmodifikation af liponsyre
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
AU2003281169A1 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
DE502007006403D1 (de) Wirkstoff-stabilisierende o/w-emulsionen ii
PT941975E (pt) Cimento para injeccao contendo inibidores de corrosao

Legal Events

Date Code Title Description
FC Refusal